Completed PHASE4 INTERVENTIONAL 3-arm
NCT05939817
The Effect of Intralesian Injection of Umbilical Cord Mesenchymal Stem Cells, Its Conditioned Medium, and Triamcinolone Acetonide on Type 1:3 Collagen Ratio and Interleukin-10 Levels in Keloid: A Randomised Controlled Trial
Sponsor: Indonesia University
Interventions
Triamcinolone Acetonide (TA) umbilical cord-derived mesenchymal stem cells (UC-MSC) umbilical cord-derived mesenchymal stem cells conditioned medium (UC-CM)
Updated 3 times since 2023 Last updated: Jul 1, 2023 Started: Oct 1, 2021 Primary completion: Jun 9, 2022 Completion: Jun 9, 2022
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
This PHASE4 trial investigates Keloid and Stem Cell and is currently completed. Indonesia University leads this study, which shows 3 recorded versions since 2021 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
3 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Aug 2023 — Jul 2024 [monthly]
Completed PHASE4
First recorded
Oct 2021
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- Indonesia University
- Rumah Sakit Pusat Angkatan Darat Gatot Soebroto
Data source: Rumah Sakit Pusat Angkatan Darat Gatot Soebroto
For direct contact, visit the study record on ClinicalTrials.gov .